We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. On December 15, 2025, UBS reaffirmed its ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

Semaglutide is the active ingredient in Wegovy® and Ozempic® and, unlike any other molecule in the GLP-1 class, has FDA-approved medicines with indications for patients with obesity (Wegovy®), type 2 ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...